{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:30:55Z","timestamp":1746793855467},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"DOI":"10.7759\/cureus.58834","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:29:31Z","timestamp":1713886171000},"source":"Crossref","is-referenced-by-count":1,"title":["A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment"],"prefix":"10.7759","author":[{"given":"Arshiya","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarshlata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhushan","family":"Madke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drishti M","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani D","family":"Jangid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro AM","year":"2019","unstructured":"Porro AM, Seque CA, Ferreira MC, Enokihara MM. Pemphigus vulgaris. An Bras Dermatol. 2019, 94:264-78. 10.1590\/abd1806-4841.20199011","journal-title":"An Bras Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16653","article-title":"B-cell targeted therapy of pemphigus","volume":"50","author":"Yamagami J","year":"2023","unstructured":"Yamagami J. B-cell targeted therapy of pemphigus. J Dermatol. 2023, 50:124-31. 10.1111\/1346-8138.16653","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze J","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al.. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023, 14:1004795. 10.3389\/fimmu.2023.1004795","journal-title":"Front Immunol"},{"key":"ref4","unstructured":"Clinical Trials. A Study of Rituximab (MabThera\u00ae\/Rituxan\u00ae) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate (SCORE). (2015). Accessed: January 22, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00578305."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill JT","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al.. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62:222-33. 10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107755","article-title":"Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study","volume":"96","author":"Aryanian Z","year":"2021","unstructured":"Aryanian Z, Balighi K, Daneshpazhooh M, et al.. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study. Int Immunopharmacol. 2021, 96:107755. 10.1016\/j.intimp.2021.107755","journal-title":"Int Immunopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.07931.x","article-title":"Efficacy and safety of rituximab in pemphigus: Experience of the German Registry of Autoimmune Diseases","volume":"10","author":"Kasperkiewicz M","year":"2012","unstructured":"Kasperkiewicz M, Eming R, Behzad M, et al.. Efficacy and safety of rituximab in pemphigus: Experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012, 10:727-32. 10.1111\/j.1610-0387.2012.07931.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts A","year":"2018","unstructured":"Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horv\u00e1th B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018, 9:248. 10.3389\/fimmu.2018.00248","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.034","article-title":"Refractory pemphigus vulgaris successfully treated with ofatumumab","volume":"6","author":"Klufas DM","year":"2020","unstructured":"Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020, 6:734-6. 10.1016\/j.jdcr.2020.05.034","journal-title":"JAAD Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi K","year":"2019","unstructured":"Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019, 10:978. 10.3389\/fimmu.2019.00978","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.901239","article-title":"Immunotherapy for pemphigus: Present and future","volume":"9","author":"Yuan H","year":"2022","unstructured":"Yuan H, Pan M, Chen H, Mao X. Immunotherapy for pemphigus: Present and future. Front Med. 2022, 9:901239. 10.3389\/fmed.2022.901239","journal-title":"Front Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000099591","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"214","author":"Marzano AV","year":"2007","unstructured":"Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007, 214:310-8. 10.1159\/000099591","journal-title":"Dermatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100813","article-title":"Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine","volume":"46","author":"Kuriyama K","year":"2022","unstructured":"Kuriyama K, Kitamura Y, Tsuji T, et al.. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. Curr Probl Cancer. 2022, 46:100813. 10.1016\/j.currproblcancer.2021.100813","journal-title":"Curr Probl Cancer"},{"key":"ref14","unstructured":"Rituximab. (2023). Accessed. December 23, 2023: https:\/\/go.drugbank.com\/drugs\/DB00073."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny T","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002, 13:S3-10. 10.1097\/00001813-200211002-00002","journal-title":"Anticancer Drugs"},{"key":"ref16","unstructured":"Research C for DE and. Rituximab (marketed as Rituxan) Information. FDA. Published Online First. (2023). Accessed: March 17, 2024: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/rituximab-marketed-rituxan-inform...."},{"key":"ref17","unstructured":"AMGEN. FDA approves Riabnitm (rituximab-arrx), a biosimilar to Rituxan\u00ae (rituximab), for adults with moderate to severe rheumatoid arthritis. (2023). Accessed: January 22, 2024: https:\/\/www.amgen.com\/newsroom\/press-releases\/2022\/06\/fda-approves-riabni-rituximabarrx-a-biosimilar-to-rituxan-ritux...."},{"key":"ref18","article-title":"XPharm: The comprehensive pharmacology reference","author":"Enna SJ","year":"2008","unstructured":"Enna SJ, Bylund DB, Elsevier Science (Firm). XPharm: The comprehensive pharmacology reference\r\n. Elsevier, Amsterdam; 2008."},{"key":"ref19","unstructured":"Mechanism of Action | KESIMPTA\u00ae (ofatumumab) | HCP. (2023). Accessed. December 23, 2023: https:\/\/www.kesimptahcp.com\/mechanism-of-action."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.4.8895","article-title":"Ofatumumab","volume":"1","author":"Zhang B","year":"2009","unstructured":"Zhang B. Ofatumumab. MAbs. 2009, 1:326-31. 10.4161\/mabs.1.4.8895","journal-title":"MAbs"},{"key":"ref21","unstructured":"Ofatumumab. (2023). Accessed. December 23, 2023: https:\/\/go.drugbank.com\/drugs\/DB06650."},{"key":"ref22","article-title":"Ocrelizumab","author":"Flynn JP","year":"2023","unstructured":"Flynn JP, Gerriets V. Ocrelizumab. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref23","unstructured":"Proposed Mechanism of Action (MOA) | OCREVUS\u00ae (ocrelizumab). ocrevus. (2023). Accessed. December 20, 2023: https:\/\/www.ocrevus-hcp.com\/about\/moa.html."},{"key":"ref24","unstructured":"Genentech. Ocrevus\u00ae (ocrelizumab). (2023). Accessed: December 24, 2023: https:\/\/www.gene.com\/media\/product-information\/ocrevus."},{"key":"ref25","unstructured":"OCREVUS\u00ae (ocrelizumab) | Multiple Sclerosis (MS) Treatment. (2023). Accessed. December 24, 2023: https:\/\/www.ocrevus.com\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715586528","article-title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: Overview and perspective","volume":"6","author":"Owen CJ","year":"2015","unstructured":"Owen CJ, Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: Overview and perspective. Ther Adv Hematol. 2015, 6:161-70. 10.1177\/2040620715586528","journal-title":"Ther Adv Hematol"},{"key":"ref27","unstructured":"Obinutuzumab (GAZYVA\u00ae) | Available Agents | NCI Formulary. (2023). Accessed. December 20, 2023: https:\/\/nciformulary.cancer.gov\/available_agents\/Obinutuzumab.htm."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type ii anti-CD20 monoclonal antibody, for the treatment of patients with b-cell malignancies","volume":"34","author":"Tobinai K","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type ii anti-CD20 monoclonal antibody, for the treatment of patients with b-cell malignancies. Adv Ther. 2017, 34:324-56. 10.1007\/s12325-016-0451-1","journal-title":"Adv Ther"},{"key":"ref29","unstructured":"GAZYVA\u00ae (obinutuzumab) Treatment, Indications, Dosing &amp; Safety. (2023). Accessed. December 24, 2023: https:\/\/www.gazyva.com\/."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.591971","article-title":"Milestones in personalized medicine in pemphigus and pemphigoid","volume":"11","author":"Bieber K","year":"2020","unstructured":"Bieber K, Kridin K, Emtenani S, Boch K, Schmidt E, Ludwig RJ. Milestones in personalized medicine in pemphigus and pemphigoid. Front Immunol. 2020, 11:591971. 10.3389\/fimmu.2020.591971","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour S","year":"2017","unstructured":"Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. Int Immunopharmacol. 2017, 53:133-42. 10.1016\/j.intimp.2017.10.027","journal-title":"Int Immunopharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka LR","year":"2012","unstructured":"Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther. 2012, 2:17. 10.1007\/s13555-012-0017-3","journal-title":"Dermatol Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00751-7","article-title":"Review of an anti-CD20 monoclonal antibody for the treatment of autoimmune diseases of the skin","volume":"24","author":"Ly S","year":"2023","unstructured":"Ly S, Nedosekin D, Wong HK. Review of an anti-CD20 monoclonal antibody for the treatment of autoimmune diseases of the skin. Am J Clin Dermatol. 2023, 24:247-73. 10.1007\/s40257-022-00751-7","journal-title":"Am J Clin Dermatol"},{"key":"ref34","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: A systematic review and meta-analysis","volume":"19","author":"Magdalena C","year":"2022","unstructured":"Magdalena C, Clarissa A, Sutandi N. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: A systematic review and meta-analysis. Innov Clin Neurosci. 2022, 19:51-64.","journal-title":"Innov Clin Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova G","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: An \"enigma\" of B-cell biology and targeted therapy. Haematologica. 2020, 105:1494-506. 10.3324\/haematol.2019.243543","journal-title":"Haematologica"},{"key":"ref36","unstructured":"AJMC. Advances and Limitations in CD20-Targeted CAR T-Cell Therapy. (2022). Accessed: December 24, 2023: https:\/\/www.ajmc.com\/view\/advances-and-limitations-in-cd20-targeted-car-t-cell-therapy."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221101138","article-title":"Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary","volume":"28","author":"Lycke J","year":"2022","unstructured":"Lycke J, Svenningsson A. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary. Mult Scler. 2022, 28:1177-8. 10.1177\/13524585221101138","journal-title":"Mult Scler"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221092092","article-title":"Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: An observational study","volume":"15","author":"Moser T","year":"2022","unstructured":"Moser T, O'Sullivan C, Otto F, et al.. Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: An observational study. Ther Adv Neurol Disord. 2022, 15:10.1177\/17562864221092092","journal-title":"Ther Adv Neurol Disord"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103418","article-title":"Derisking CD20-therapies for long-term use","volume":"57","author":"Smets I","year":"2022","unstructured":"Smets I, Giovannoni G. Derisking CD20-therapies for long-term use. Mult Scler Relat Disord. 2022, 57:103418. 10.1016\/j.msard.2021.103418","journal-title":"Mult Scler Relat Disord"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S75908","article-title":"Management of pemphigus vulgaris: Challenges and solutions","volume":"8","author":"Gregoriou S","year":"2015","unstructured":"Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: Challenges and solutions. Clin Cosmet Investig Dermatol. 2015, 8:521-7. 10.2147\/CCID.S75908","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.581820","article-title":"Therapy changes during pemphigus management: A retrospective analysis","volume":"7","author":"Scarpone R","year":"2020","unstructured":"Scarpone R, Francuzik W, Worm M, Heine G. Therapy changes during pemphigus management: A retrospective analysis. Front Med. 2020, 7:581820. 10.3389\/fmed.2020.581820","journal-title":"Front Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2022.01.340","article-title":"Pemphigus vulgaris: Challenges in diagnosis and treatment","volume":"134","author":"Einsfeld V","year":"2022","unstructured":"Einsfeld V, Gueburg MI, Sassi LM, Schussel JL, Stramandinoli RT, Dissenha JL, Zanferrari FL. Pemphigus vulgaris: Challenges in diagnosis and treatment. Oral Surg Oral Med Oral Radiol. 2022, 134:144. 10.1016\/j.oooo.2022.01.340","journal-title":"Oral Surg Oral Med Oral Radiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall MJ","year":"2017","unstructured":"Marshall MJ, Stopforth RJ, Cragg MS. Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?. Front Immunol. 2017, 8:1245. 10.3389\/fimmu.2017.01245","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: Historical and future perspectives","volume":"95","author":"Lim SH","year":"2010","unstructured":"Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica. 2010, 95:135-43. 10.3324\/haematol.2008.001628","journal-title":"Haematologica"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22912","article-title":"Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective","volume":"9","author":"Ghane Y","year":"2023","unstructured":"Ghane Y, Heidari N, Heidari A, Sadeghi S, Goodarzi A. Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective. Heliyon. 2023, 9:e22912. 10.1016\/j.heliyon.2023.e22912","journal-title":"Heliyon"},{"key":"ref46","article-title":"Pemphigus: Updated review and emerging therapies","volume":"44","author":"D\u2019Amiano NM","year":"2023","unstructured":"D\u2019Amiano NM, Lai J, Cohen BA. Pemphigus: Updated review and emerging therapies. Dermatol Times. 2023, 44:102.","journal-title":"Dermatol Times"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.708071","article-title":"Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus","volume":"8","author":"Patsatsi A","year":"2021","unstructured":"Patsatsi A, Murrell DF. Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus. Front Med. 2021, 8:708071. 10.3389\/fmed.2021.708071","journal-title":"Front Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer J","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023, 19:289-304. 10.1038\/s41582-023-00800-7","journal-title":"Nat Rev Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245364-a-comprehensive-review-on-the-efficacy-of-anti-cd20-therapies-in-pemphigus-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:29:38Z","timestamp":1713886178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245364-a-comprehensive-review-on-the-efficacy-of-anti-cd20-therapies-in-pemphigus-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.58834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}